Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation
Graphical abstract
Introduction
Lower respiratory tract infections (or lung infections) cause high mortality and morbidity (Liang et al., 2011, Mizgerd, 2006, WHO, 2014). Antibiotics administered via systemic routes are often not effective for lung infections, as for many antibiotics such as the polymyxins (polymyxin B and colistin) only a small fraction of the drug is available at the sites of infection (i.e. in the lungs) (Velkov et al., 2015). Simply increasing parenteral dose often causes severe systemic adverse effects (Traini and Young, 2009). For instance, high-dose parenteral colistin can lead to neurotoxicity and nephrotoxicity (Garonzik et al., 2011).
Colistin is often used for treatment of respiratory infections caused by multidrug-resistant (MDR) Gram-negative bacteria (Levin et al., 1999, Velkov et al., 2015). Recently, there is a marked increase in the incidence of colistin-resistant infections (Cai et al., 2012, Marchaim et al., 2011, Paterson and Harris, 2016). Due to the dry development pipeline of novel antibiotics, combination therapy can be a practical and swift approach for treating the infections caused by colistin-resistant pathogens (Cai et al., 2012). However, synergistic antibacterial effects of systemically administered combination antibiotics can be compromised due to the different pharmacokinetic profiles (Weers, 2015), which may not allow both drugs to attain effective drug concentrations at the same time at the infection sites.
Antimicrobial therapy via the inhalation route has attracted increasing attentions for the treatment of lower respiratory infections (Velkov et al., 2015, Zhou et al., 2015). Inhalation therapy substantially improves drug concentration on the airway surfaces with much reduced systemic exposure, hence maximizes the treatment efficacy and reduces the systemic toxicities (Cipolla and Chan, 2013, Montgomery et al., 2014, Yapa et al., 2013). Additionally, inhalation therapy may be able to deliver combinational antibiotics to the same targeted infection sites simultaneously allowing greater opportunity to achieve intended synergistic effects. In addition, dry powder inhalers (DPIs) may enable the delivery of high-doses of antibiotics directly to the respiratory tracts (Zhou et al., 2015).
Typically, the inhaled drug particles produced by traditional jet-milling approach are highly cohesive and have poor flowability and poor aerosolization performance (Lin et al., 2015). Addition of excipients such as fine lactose particles may improve the aerosolization of cohesive powders to some extent (de Boer et al., 2012, Grasmeijer et al., 2014, Smyth and Hickey, 2005). However, for high-dose drugs like antibiotics, addition of excipients may increase the inhalation powder mass that needs an excessive number of inhalations to complete the dose and a bulky inhaler to accommodate the large dose (Zhou et al., 2015).
Our earlier studies have indicated that the spray dried colistin particles without any excipient had high aerosol performance with fine particle fraction (FPF) >80% with an Aerolizer® device (Zhou et al., 2013). It was proposed that such high aerosol performance of the spray dried colistin powders is attributed to its surfactant-like properties (Mestres et al., 1998, Wallace et al., 2010), which allows self-assembly of non-polar tail at the air-liquid interface during spray drying resulting in the formation of low surface energy particles (Jong et al., 2016). Previous studies have shown that surface-active components could also potentially self-assemble on the surface, when co-sprayed with a secondary component altering its surface physico-chemical and aerosolization properties (Chew et al., 2005a, Chew et al., 2005b, Momin et al., 2018a, Momin et al., 2018b, Rabbani and Seville, 2005, Sou et al., 2013, Zhou et al., 2016). The aim of this study was to investigate the effect of colistin on the aerosol performance of the co-spray dried formulations in synergistic combination with meropenem (Lenhard et al., 2016).
In this study, colistin was co-spray dried with meropenem to develop combinational DPI formulations. The resultant DPI formulations were characterized regarding particle size, morphology, surface chemical composition and specific surface area. The in-vitro aerosol performance and in-vitro antibacterial activity were characterized.
Section snippets
Materials
Colistin sulfate and meropenem trihydrate were purchased from ßetaPharma® (Shanghai) Co., Ltd (Wujiang City, JiangSu Province, China). Acetonitrile (HPLC grade) and sodium sulfate were purchased from Fisher Scientific (Fair Lawn, New Jersey, USA). Tryptone soy broth and Mueller-Hinton Broth were supplied by Oxoid Ltd, Basingstoke, UK and glycerol by Astral Scientific Pty Ltd, Taren Point, Australia.
Time-kill assays
Clinical isolates of A. baumannii N16870 and Pseudomonas aeruginosa 19147 were stored in tryptone
Time kill assay
Fig. 1 shows the time-kill profiles against clinical isolates of A. baumannii N16870 and P. aeruginosa 19147. For A. baumannii N16870, meropenem showed no antibacterial effect at 16 mg/L in 24 h, and marginal antibacterial activity at 48 mg/L in 2 h, albeit regrowth was observed in 4 h (Fig. 1A). Colistin showed bacterial killing at both 16 and 48 mg/L; but at 16 mg/L regrowth was evident in 4 h. The combination of Colistin:Meropenem_1:1 (16:16 mg/L) demonstrated superior antibacterial activity
Discussion
Combination antibiotic therapies are increasingly used to combat MDR Gram-negative lung infections (Mouton, 1999). This has spurred the search for effective colistin combinations that exhibit greater bacterial killing, improved safety and superior pharmacokinetics (Biswas et al., 2012, Zhou et al., 2014, Zhou et al., 2016). Typically, the antibiotics with different mechanisms of action can act synergistically to greatly enhance antibacterial killing. Colistin is a lipopeptide antibiotic that
Conclusions
In the present study, we developed and characterized co-spray dried colistin and meropenem DPI formulations which showed superior antibacterial activity. Incorporation of colistin improved the aerosolization performance of meropenem as evidenced by an almost two-fold increase in FPF, attributable to the enrichment of colistin on the particle surface and the increased porosity. FT-IR spectra demonstrated intermolecular interactions between colistin and meropenem. Such synergistic antimicrobial
Acknowledgement
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI132681. Jian Li and Tony Velkov are supported by a research grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI111965). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of
References (63)
- et al.
Ultrahigh antibacterial efficacy of meropenem-loaded chitosan nanoparticles in a septic animal model
Carbohydr. Polym.
(2017) - et al.
Effect of amino acids on the dispersion of disodium cromoglycate powders
J. Pharm. Sci.
(2005) - et al.
A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect?
Adv. Drug Deliv. Rev.
(2012) - et al.
Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery
Int. J. Pharm.
(2011) - et al.
Nanoscale investigation of the interaction of colistin with model phospholipid membranes by Langmuir technique, and combined infrared and force spectroscopies
Biochim. Biophys. Acta Biomembr.
(2016) - et al.
Inhalative meropenem–tobramycin–colistin combination improves lung function in chronic Pseudomonas aeruginosa colonization
J. Cystic Fibrosis
(2015) - et al.
Investigation of the changes in aerosolization behavior between the jet-milled and spray-dried colistin powders through surface energy characterization
J. Pharm. Sci.
(2016) - et al.
Relationship between surface concentration of L-leucine and bulk powder properties in spray dried formulations
Eur. J. Pharm. Biopharm.
(2015) - et al.
Applying surface energy derived cohesive–adhesive balance model in predicting the mixing, flow and compaction behaviour of interactive mixtures
Eur. J. Pharm. Biopharm.
(2016) - et al.
Interaction of colistin with lipids in liposomes and monolayers
Int. J. Pharm.
(1998)
Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug
Int. J. Pharm.
Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections
Int. J. Pharm.
β-Cyclodextrin complexation as an effective drug delivery system for meropenem
Eur. J. Pharm. Biopharm.
Colistin resistance: a major breach in our last line of defence
Lancet Infect. Dis.
The influence of formulation components on the aerosolisation properties of spray-dried powders
J. Controlled Release
Spray drying formulation of amorphous solid dispersions
Adv. Drug Deliv. Rev.
The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules
Eur. J. Pharm. Biopharm.
In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units
Int. J. Antimicrob. Agents
Particle formation in spray drying
J. Aerosol Sci.
Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead
Adv. Drug Deliv. Rev.
Inhaled antimicrobial therapy – barriers to effective treatment
Adv. Drug Deliv. Rev.
Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach
J. Pharm. Sci.
Inhaled formulations and pulmonary drug delivery systems for respiratory infections
Adv. Drug Deliv. Rev.
Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation
J. Pharm. Sci.
Colistin: an update on the antibiotic of the 21st century
Expert Rev. Anti-Infective Ther.
Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies
J. Antimicrob. Chemother.
The role of particle properties in pharmaceutical powder inhalation formulations
J. Aerosol Med.
Use of solid corrugated particles to enhance powder aerosol performance
Pharm. Res.
How much particle surface corrugation is sufficient to improve aerosol performance of powders?
Pharm. Res.
Solid-state stability study of meropenem – solutions based on spectrophotometric analysis
Chem. Cent. J.
Cited by (19)
Quality by design – Spray drying of ciprofloxacin-quercetin fixed-dose combination intended for inhalation
2023, International Journal of PharmaceuticsSynergetic dual antibiotics-loaded chitosan/poly (vinyl alcohol) nanofibers with sustained antibacterial delivery for treatment of XDR bacteria-infected wounds
2023, International Journal of Biological MacromoleculesCitation Excerpt :Moreover, in the FTIR spectra of CS/PVA/AB, different peaks for the colistin were at 1645.0 (amid I CO), 1068.4 cm−1 (CN) and 2956.3 (CH). For meropenem, the peaks of β-lactam CN stretching at 1253.5 cm−1, β -lactam CO stretching at 1756.8 cm−1, and OH were observed at 2965.9 cm−1 [33]. Fig. 2A presents the effect of antibiotic concentrations on the swelling ratio of the CS/PVA.
Amorphous solid dispersion dry powder for pulmonary drug delivery: Advantages and challenges
2020, International Journal of PharmaceuticsCitation Excerpt :Moreover, hydrophobic azithromycin (at a ratio of ≥ 50% w/w) occupies the surface of co-spray dried azithromycin-colistin particles and prevents moisture-induced reduction of aerosolization efficiency (Zhou et al., 2016). Surprisingly, it was reported that colistin on the surface of colistin-meropenem co-sprayed particles (at a ratio of 1: 1 and 3: 1 w/w, respectively) enhanced the FPF of meropenem by two-fold compared to the spray dried meropenem (Mangal et al., 2018b). This observation was attributed to the increase in particle porosity with the increase in colistin concentration with a consequent reduction in particle daer.
Development and characterization of meropenem dry powder inhaler formulation for pulmonary drug delivery
2020, International Journal of PharmaceuticsQuantification of surface composition and surface structure of inhalation powders using TOF-SIMS
2020, International Journal of PharmaceuticsCitation Excerpt :For organic molecules, the TOF-SIMS spectrum can vary with the matrix in which the analyte molecule finds itself, but only if specific interactions such as hydrogen-bonding or cationization from neighboring molecules are possible (Eynde, 2001). A number of non-quantitative analyses of pharmaceutical powders using TOF-SIMS have been reported in the literature (Bhujbal et al. 2018; Eedara et al. 2018; Jetzer et al. 2018; Li et al. 2016; Mangal et al. 2018; Mangal et al. 2019; Mohammad et al. 2018a; Mohammad et al. 2018b; Wang et al. 2016; Yu et al. 2017: Yu et al. 2018; Zhou et al. 2016). All but two of these studies (Jetzer et al. 2018; Yu et al., 2018) use XPS for quantification.
Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections
2019, European Journal of Pharmaceutics and BiopharmaceuticsCitation Excerpt :However, P. aeruginosa rapidly acquires antibiotic-resistance to fluoroquinolones and these “superbugs” can readily survive under monotherapy [10,11]. To prevent emergence of drug resistance, some concomitant formulation of inhaled antimicrobials have been studied [12–15]. Ciprofloxacin was also previously co-spray dried with doxycycline hydrochloride, but no synergy was observed against P. aeruginosa [14].